Inhibitory and inductive effects of rifampin on the pharmacokinetics of bosentan in healthy subjects.
about
OATPs, OATs and OCTs: the organic anion and cation transporters of the SLCO and SLC22A gene superfamiliesRecent advances in understanding hepatic drug transportSimultaneous assessment of uptake and metabolism in rat hepatocytes: a comprehensive mechanistic modelBosentan and Rifampin Interactions Modulate Influx Transporter and Cytochrome P450 Expression and Activities in Primary Human Hepatocytes.Organic anion transporting polypeptide 1B3 can form homo- and hetero-oligomersInfluence of OATP1B1 Function on the Disposition of Sorafenib-β-D-GlucuronideEffect of cyclosporine and rifampin on the pharmacokinetics of macitentan, a tissue-targeting dual endothelin receptor antagonist.Pharmacologic treatments for pulmonary hypertension: exploring pharmacogenomicsEffect of rifampicin on the pharmacokinetics and pharmacodynamics of saxagliptin, a dipeptidyl peptidase-4 inhibitor, in healthy subjects.Sildenafil and bosentan plasma concentrations in a human immunodeficiency virus- infected patient with pulmonary arterial hypertension treated with ritonavir-boosted protease inhibitorElucidating rifampin's inducing and inhibiting effects on glyburide pharmacokinetics and blood glucose in healthy volunteers: unmasking the differential effects of enzyme induction and transporter inhibition for a drug and its primary metabolite.Role of OATP transporters in the disposition of drugs.Bosentan in the treatment of pulmonary arterial hypertension with the focus on the mildly symptomatic patient.Evaluation of the endothelin receptor antagonists ambrisentan, bosentan, macitentan, and sitaxsentan as hepatobiliary transporter inhibitors and substrates in sandwich-cultured human hepatocytes.Bosentan for the treatment of adult pulmonary hypertension.Current understanding of hepatic and intestinal OATP-mediated drug-drug interactions.Clinical pharmacokinetics and drug-drug interactions of endothelin receptor antagonists in pulmonary arterial hypertension.Drug interactions and protease inhibitors used in the treatment of hepatitis C: how to manage?Effect of gemfibrozil or rifampicin on the pharmacokinetics of selexipag and its active metabolite in healthy subjects.Causes and Consequences of Variability in Drug Transporter Activity in Pediatric Drug Therapy.Establishment and assessment of a new human embryonic stem cell-based biomarker assay for developmental toxicity screening.Fentanyl pharmacokinetics is not dependent on hepatic uptake by organic anion-transporting polypeptide 1B1 in human beings.Phase I and II metabolism and MRP2-mediated export of bosentan in a MDCKII-OATP1B1-CYP3A4-UGT1A1-MRP2 quadruple-transfected cell line.In vitro and in silico strategies to identify OATP1B1 inhibitors and predict clinical drug-drug interactions.The effect of acute administration of rifampicin and imatinib on the enterohepatic transport of rosuvastatin in vivo.Increased systemic exposure of fimasartan, an angiotensin II receptor antagonist, by ketoconazole and rifampicin.Safety and efficacy evaluation of ambrisentan in pulmonary hypertension.Rifampin's acute inhibitory and chronic inductive drug interactions: experimental and model-based approaches to drug-drug interaction trial design.Effects of one-time apple juice ingestion on the pharmacokinetics of fexofenadine enantiomers.Comparison of exposure response relationship of atrasentan between North American and Asian populations.Tissue-specific changes in mRNA expression of Abc and Slc transporters in murine pulmonary tuberculosis.
P2860
Q27001267-CAD3AEE5-BD11-402B-B2B5-6F7BD0130680Q28077066-4666FC86-D513-4590-ADD6-9D41D16DBBF7Q30511951-6C761FC8-DED3-48DE-9DC8-87455E2189F8Q33655897-ABFCF509-3E79-49C0-8BEB-0F848ACF5B6DQ33828993-97BF40C9-8EE2-42CE-9F72-AEAF46F5268CQ33891564-CE68100F-7D79-45DB-A2C9-13ADE053A8D8Q34242199-B3C56467-58AB-4208-9A58-FCAE9A342002Q34344390-E5136C9B-50D1-4F5B-B874-4B88B69F8CA7Q35120613-17EC5203-CBBD-4B88-932D-FE9529DAC5C5Q35290066-6362119B-A45B-45EE-BA03-4448781612DCQ36639493-BBF34ACF-1F25-4222-A832-5892341B3A91Q37074085-60C677F1-5141-468F-A992-32FFFB53A212Q37302470-E05598E1-95F7-4489-84B5-A902EAB311CAQ37534587-0764935A-9421-4BC1-8AA5-BA1967BB45AEQ37822722-6B0560E2-F518-43F6-B361-15E51219EFA5Q37960129-BDF6C413-CD5E-4011-96DC-AAAFA2DC1736Q37972127-2DED09C4-BA41-425B-BB9E-0259A0242FB9Q38210969-B72F547A-E6BC-4BA0-BBC4-A0E3FC64846AQ38675399-58AA172E-BA83-45C5-92C0-DC4CC713F4ADQ38888350-687D9D0B-5D3C-420B-9BB3-DADF12B0E544Q39079366-08A641BE-03B0-4D2A-89F1-D3DD490A24FAQ39182431-BDEEA9A3-3465-4C4F-B1B9-0D76642EBD88Q39198686-E035D3BB-5AA5-4D3F-8B3C-5C968924E95CQ40620508-8860B3BC-DF99-49AF-9DDE-3FCB370BACCAQ43003337-EB021C86-4335-4EFF-B97C-ABB013208CC6Q46132298-21E68348-C20E-4E77-BE8F-68FEEF00E992Q47305826-B2A05FFE-0EF4-4216-85A2-D1A1685FC161Q48301397-8607EB70-25B1-48A6-8518-ADD4AFCFB7B6Q48600898-8B5EDB9C-BFD7-4E38-8EBD-C3036796AD0CQ48650147-75DDF452-06E7-4644-9525-2E00DB894C07Q54474191-37DF779A-01E7-4E97-B0B7-CDCE58661128
P2860
Inhibitory and inductive effects of rifampin on the pharmacokinetics of bosentan in healthy subjects.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh-hant
name
Inhibitory and inductive effec ...... bosentan in healthy subjects.
@en
Inhibitory and inductive effec ...... bosentan in healthy subjects.
@nl
type
label
Inhibitory and inductive effec ...... bosentan in healthy subjects.
@en
Inhibitory and inductive effec ...... bosentan in healthy subjects.
@nl
prefLabel
Inhibitory and inductive effec ...... bosentan in healthy subjects.
@en
Inhibitory and inductive effec ...... bosentan in healthy subjects.
@nl
P2093
P2860
P356
P1476
Inhibitory and inductive effec ...... bosentan in healthy subjects.
@en
P2093
H Dietrich
J Dingemanse
P L M van Giersbergen
R Schneiter
P2860
P304
P356
10.1038/SJ.CLPT.6100075
P407
P577
2007-01-24T00:00:00Z